Recently, an open-label, randomized phase III clinical trial (KEYNOTE-426) compared the efficacy of pembrolizumab (Keytruda, a PD-1 blocker) plus axitinib (a multitargeted tyrosine kinase inhibitor for VEGFR, c-kit, and PDGFR, N = 432) with sunitinib (a multitargeted tyrosine kinase inhibitor for PDGFR, VEGFR, and c-kit, N = 429) in previously untreated advanced RCC patients [16]. The gene discussed is KIT; the disease is renal cell adenocarcinoma.